The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome (MF/SS), the most common type of PCL, none exist for the other PCLs. In addition, staging in the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.Copyright © 2021 American Society of Hematology.
About The Expert
Elise A Olsen
Sean Whittaker
Rein Willemze
Lauren Pinter-Brown
Francine M Foss
Larisa J Geskin
Lawrence Howard Schwartz
Steven M Horwitz
Joan Guitart
John Zic
Youn H Kim
Gary S Wood
Madeleine Duvic
Weiyun Z Ai
Michael Girardi
Alejandro Gru
Emmanuella Guenova
Emmilia Hodak
Richard T Hoppe
Werner Kempf
Ellen J Kim
Mary Jo Lechowicz
Pablo L Ortiz-Romero
Evangelia Papadavid
Pietro Quaglino
Mark R Pittelkow
H Miles Prince
Jose Antonio Sanches
Makoto Sugaya
Maarten H Vermeer
Jasmine Zain
Robert Knobler
Rudolf Stadler
Martine Bagot
Julia J Scarisbrick
References
PubMed